Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.31 |
| ▸ | BHMT | Q93088 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16279005 | 0.87 | GABRR1 (0.32) | KDM7APHF8KDM2AGABRR1BHMT | |
| SCHEMBL16279002 | 0.87 | GABRR1 (0.32) | KDM7APHF8KDM2AGABRR1BHMT | |
| SCHEMBL25466927 | 0.86 | CACNA2D1 (0.30) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Negamycin SCHEMBL21578042 | 0.86 | GABRR1 (0.38) | GABRR1LMNACACNA2D1CACNB3CACNA1C | |
| Negamycin SCHEMBL1650147 | 0.86 | GABRR1 (0.38) | GABRR1LMNACACNA2D1CACNB3CACNA1C | |
| SCHEMBL24176384 | 0.86 | CACNA2D1 (0.30) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Negamycin SCHEMBL564074 | 0.86 | GABRR1 (0.38) | GABRR1LMNACACNA2D1CACNB3CACNA1C | |
| SCHEMBL7123600 | 0.85 | — | — | |
| SCHEMBL7116470 | 0.85 | — | — | |
| SCHEMBL21577901 | 0.84 | GSR (0.33) | BHMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371274-B2 | Compound having read-through activity | THE UNIVERSITY OF TOKYO (JP) | 2016-06-21 | — | — | US | disclosed |
| US-9371274-B2 | Compound having read-through activity | THE UNIVERSITY OF TOKYO (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20140364642-A1 | COMPOUND HAVING READ-THROUGH ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364642-A1 | COMPOUND HAVING READ-THROUGH ACTIVITY | UPF1, NUDT21, GBA2 | KDM7A 2353/4885PHF8 2672/4885KDM2A 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.